EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

BIRC5 facilitates cisplatin‐chemoresistance in a m 6 A ‐dependent manner in ovarian cancer

Yadan Fan iD, Yinglian Pan, Liping Jia, Shuzhen Gu, Binxin Liu, Ziman Mei, Chunyan Lv, Haohao Huang iD, Genhai Zhu, Qingchun Deng

Cancer Medicine · 2024-01 · 13 (1)

DOI: 10.1002/cam4.6811 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, online erschienen am 19.12.2023. Verfasst von Yadan Fan und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gynecology, The Second Affiliated Hospital of Hainan Medical University, Haikou, China. Hauptthemen laut MEDLINE: Cisplatin, Drug Resistance, Neoplasm, Ovarian Neoplasms, Survivin. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: General Hospital of Central Theater Command of Chinese People's Liberation Army Foundation, Nature Science Foundation of Hubei Province, the China Postdoctoral Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cisplatin‐based chemotherapy is the standard treatment for metastatic ovarian cancer (OC). However, chemoresistance continues to pose significant clinical challenges. Recent research has highlighted the baculoviral inhibitor of the apoptosis protein repeat‐containing 5 (BIRC5) as a member of the inhibitor of the apoptosis protein (IAP) family. Notably, BIRC5, which has robust anti‐apoptotic capabilities, is overexpressed in numerous cancers. Its dysfunction has been linked to challenges in cancer treatment. Yet, the role of BIRC5 in the chemoresistance of OC remains elusive. In our present study, we observed an upregulation of BIRC5 in cisplatin‐resistant cell lines. This upregulation was associated with enhanced chemoresistance, which was diminished when the expression of BIRC5 was silenced. Intriguingly, BIRC5 exhibited a high number of N6‐methyladenosine (m 6 A) binding sites. The modification of m 6 A was found to enhance the expression of BIRC5 by recognizing and binding to the 3′‐UTR of mRNA. Additionally, the insulin‐like growth factor 2 mRNA‐binding protein 1 (IGF2BP1) was shown to stabilize BIRC5 mRNA, synergizing with METTL3 and intensifying chemoresistance. Supporting these in vitro findings, our in vivo experiments revealed that tumors were significantly smaller in size and volume when BIRC5 was silenced. This reduction was notably counteracted by co‐silencing BIRC5 and overexpressing IGF2BP1. Our results underscored the pivotal role of BIRC5 in chemoresistance. The regulation of its expression and the stability of its mRNA were influenced by m 6 A modifications involving both METTL3 and IGF2BP1. These insights presented BIRC5 as a promising potential therapeutic target for addressing cisplatin resistance in OC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CisplatinDrug Resistance, NeoplasmOvarian NeoplasmsSurvivinRNA-Binding ProteinsGene Expression Regulation, NeoplasticFemaleHumansCell Line, TumorAnimalsMiceXenograft Model Antitumor AssaysAntineoplastic Agents3' Untranslated RegionsMice, NudeRNA, MessengerApoptosisAdenosineMethyltransferases

Stichwörter der Autor:innen

BIRC5IGF2BP1METTL3chemoresistanceovarian cancer

Substanzen

CisplatinSurvivinRNA-Binding ProteinsBIRC5 protein, humanN-methyladenosineMETTL3 protein, humanIGF2BP1 protein, humanAntineoplastic Agents3' Untranslated RegionsRNA, Messenger

Autor:innen und Institutionen

  • Department of Gynecology, The Second Affiliated Hospital of Hainan Medical University, Haikou, China.
  • Department of Oncology, The First Affiliated Hospital of Hainan Medical College, Haikou, China.
  • Department of Neurosurgery, General Hospital of Central Theater Command of Chinese People's Liberation Army, Wuhan, China.
  • Department of Gynecology, Hainan General Hospital, Hainan Affiliated Hospital of Hainan Medical University, Haikou, China.

ORCID-Profile: Yadan Fan, Haohao Huang

Förderung

  • General Hospital of Central Theater Command of Chinese People's Liberation Army Foundation
  • Nature Science Foundation of Hubei Province
  • the China Postdoctoral Science Foundation
  • The Hainan Health Commission Project
  • The Hainan Provincial Key Research and Development Program Project Fund
  • The High-level Talents Program of Hainan Province Natural Science Foundation
  • The National Natural Science Foundation of China

Zitieren

APA

Fan, Y., Pan, Y., Jia, L., Gu, S., Liu, B., Mei, Z., Lv, C., Huang, H., Zhu, G., & Deng, Q. (2024). BIRC5 facilitates cisplatin‐chemoresistance in a m 6 A ‐dependent manner in ovarian cancer. Cancer Medicine, 13(1). https://doi.org/10.1002/cam4.6811

Vancouver

Fan Y, Pan Y, Jia L, Gu S, Liu B, Mei Z, et al. BIRC5 facilitates cisplatin‐chemoresistance in a m 6 A ‐dependent manner in ovarian cancer. Cancer Medicine. 2024;13(1). doi:10.1002/cam4.6811

BibTeX
@article{Fan2024,
  author = {Fan, Yadan and Pan, Yinglian and Jia, Liping and Gu, Shuzhen and Liu, Binxin and Mei, Ziman and Lv, Chunyan and Huang, Haohao and Zhu, Genhai and Deng, Qingchun},
  title = {BIRC5 facilitates cisplatin‐chemoresistance in a m 6 A ‐dependent manner in ovarian cancer},
  journal = {Cancer Medicine},
  year = {2024},
  volume = {13},
  number = {1},
  doi = {10.1002/cam4.6811}
}
Kostenlos starten →